Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 41, Issue 4

Issues

PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study

Monique Vincent-Viry / Catherine Sass / Sabine Bastien / Dominique Aguillon / Gérard Siest / Sophie Visvikis
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2003.081

Abstract

This study describes the factors of variation of the enzymes related to the PON1-192 phenotype assessment, i.e., basal paraoxonase, salt-stimulated paraoxonase and arylesterase activities, and compares the PON1-192 phenotype to the PON1-192 genotype assessments in supposedly healthy subjects issued from the Stanislas cohort study. The studied population included 918 subjects, i.e., 221 families including 441 adults and 477 children aged 4 to 58 years. Potential determinants such as age, gender, body mass index, alcohol and tobacco consumption, and oral contraceptive intake have been studied. The PON ratio (salt-stimulated paraoxonase/arylesterase) was trimodally distributed and the cut-off values used to differentiate the two homozygous (AA and BB phenotypes) from the heterozygous (AB phenotype) subjects were 3.0 and 7.0 in this study. In males, basal paraoxonase and salt-stimulated paraoxonase activities were not affected by alcohol consumption and current smoking, but basal paraoxonase activity was decreased by 15% by current smoking and was increased by 15% by oral contraceptive intake in females as was the salt-stimulated paraoxonase activity. The level of discordance between phenotype and genotype assessments was 7.2% (66/918). Most of the discrepancies were observed between the BB and AB phenotypes (4.25%).

About the article

Published Online: 2005-06-01

Published in Print: 2003-04-25


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 41, Issue 4, Pages 535–540, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2003.081.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
George KALOGERAKIS, Arthur M. BAKER, Steve CHRISTOV, Kevin G. ROWLEY, Karen DWYER, Christine WINTERBOURN, James D. BEST, and Alicia J. JENKINS
Clinical Science, 2005, Volume 108, Number 6, Page 497
[2]
Carolina Schwedhelm, Katharina Nimptsch, Achim Bub, Tobias Pischon, and Jakob Linseisen
British Journal of Nutrition, 2016, Volume 115, Number 4, Page 730
[3]
Elizabete de Jesus Inês, Mônica Lopes Sampaio Silva, Joelma Nascimento de Souza, Alana Alcântara Galvão, Márcia Cristina Aquino Teixeira, and Neci Matos Soares
Acta Tropica, 2017, Volume 166, Page 1
[4]
Lucio G. Costa, Annabella Vitalone, Toby B. Cole, and Clement E. Furlong
Biochemical Pharmacology, 2005, Volume 69, Number 4, Page 541
[5]
Ildiko Seres, Gyorgy Paragh, Elaine Deschene, Tamas Fulop, and Abdelouahed Khalil
Experimental Gerontology, 2004, Volume 39, Number 1, Page 59
[7]
Eliane Albuisson, Sandy Maumus, Ndeye-Coumba Ndiaye, Bérangère Marie, Nicolas Jay, François Kohler, Gérard Siest, and Sophie Visvikis-Siest
Clinical Chemistry and Laboratory Medicine, 2008, Volume 46, Number 1
[8]
Christine Boesch-Saadatmandi, Gerald Rimbach, Charlotte Schrader, Bettina M. Kofler, Christopher K. Armah, and Anne M. Minihane
Molecular Nutrition & Food Research, 2010, Volume 54, Number 12, Page 1842
[9]
Freya Kamel and Jane A. Hoppin
Environmental Health Perspectives, 2004, Volume 112, Number 9, Page 950
[10]
Karen Huen, Kim Harley, Jordan Brooks, Alan Hubbard, Asa Bradman, Brenda Eskenazi, and Nina Holland
Environmental Health Perspectives, 2009, Volume 117, Number 10, Page 1632
[11]
Mariann Harangi, Ildikó Seres, János Harangi, and György Paragh
Cardiovascular Drugs and Therapy, 2009, Volume 23, Number 6, Page 501
[12]
Handrean Soran, Nahla N Younis, Valentine Charlton-Menys, and Paul Durrington
Current Opinion in Lipidology, 2009, Volume 20, Number 4, Page 265
[13]
Kenneth J. Mukamal, Jennifer K. Pai, Majken K. Jensen, and Eric B. Rimm
Circulation Journal, 2009, Volume 73, Number 7, Page 1302
[14]
Hossein Z. Mirdamadi, Ferenc Sztanek, Zoltan Derdak, Ildiko Seres, Mariann Harangi, and György Paragh
British Journal of Clinical Pharmacology, 2008, Volume 66, Number 3, Page 366
[15]
Selda Kiranoglu, Selma Sinan, Nahit Gencer, Feray Köckar, and Oktay Arslan
Biological & Pharmaceutical Bulletin, 2007, Volume 30, Number 6, Page 1048
[16]
M. Roest, T. M. van Himbergen, A. B. Barendrecht, P. H. M. Peeters, Y. T. van der Schouw, and H. A. M. Voorbij
European Journal of Clinical Investigation, 2007, Volume 37, Number 3, Page 187
[17]
Deidre A. Winnier, David L. Rainwater, Shelley A. Cole, Jeff T. Williams, Thomas D. Dyer, John Blangero, Jean W. MacCluer, and Michael C. Mahaney
Genetic Epidemiology, 2007, Volume 31, Number 1, Page 66
[18]
Héctor C. Cataño, Jayme L. Cueva, Anthony M. Cardenas, VÍctor Izaguirre, Amparo I. Zavaleta, Elizabeth Carranza, and Antonio F. Hernández
Environmental and Molecular Mutagenesis, 2006, Volume 47, Number 9, Page 699
[19]
Mike Mackness, Paul Durrington, and Bharti Mackness
Current Opinion in Lipidology, 2004, Volume 15, Number 4, Page 399

Comments (0)

Please log in or register to comment.
Log in